Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US trials go-ahead for Nitinol septal occluder:

This article was originally published in Clinica

Executive Summary

The FDA has agreed to trials of Nitinol's Cardioseal septal occluder. The device is a heart implant designed to close transient holes (patent foramen ovale) in the atrial septum and is being used routinely at some European hospitals, said Nitinol. The US trials will begin at up to 15 sites later in the spring, after some protocol changes demanded by the FDA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT080885

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel